Evolus Expands Skin Quality Portfolio
Evolus Secures Exclusive U.S. Rights for Profhilo, Expanding into Rapidly Growing Skin Quality Market
Key Points
The deal includes minimum purchase requirements that begin in the fourth year after launch, signaling a staged, capex-light procurement obligation rather than upfront milestone payments.
Profhilo is designed for superficial application to improve overall skin quality, focusing on hydration, elasticity, and smoothness rather than traditional volume restoration.
Profhilo has a proven global track record, with more than 4.8 million treatments administered since its 2015 launch and availability in over 70 countries.
The 8-K filing confirms Evolus has exclusive rights to develop, commercialize and distribute Profhilo in the United States and also provides rights to negotiate for additional products within the Profhilo brand family in the U.S. market.
Evolus CEO David Moatazedi characterized the move as an 'exciting new chapter' into skin quality, describing it as one of the fastest-growing and most innovative segments in injectable aesthetics.
Evolus has locked in an exclusive U.S. license to develop and sell Profhilo, a hyaluronic acid injectable made by Swiss pharma firm IBSA, according to MarketScreener. The deal gives Evolus sole rights to bring one of the world's most-used skin-quality products to American patients for the first time.
Profhilo has been given more than 4.8 million treatments since its 2015 launch and is sold in over 70 countries, TipRanks reported. Yet it has never been available in the U.S. — until now.
What Profhilo Does and Why It Matters
Profhilo is not a traditional filler. It does not add volume or sculpt facial features. Instead, it works just under the skin's surface to boost hydration, elasticity, and smoothness, according to The Dermatology Digest. Doctors call this the "skin quality" category — a fast-growing corner of injectable aesthetics.
Evolus CEO David Moatazedi called the move an "exciting new chapter" into skin quality. He described it as "one of the fastest-growing and most innovative segments in injectable aesthetics." Evolus already sells neurotoxins and dermal fillers. Profhilo adds a third, distinct product type to its lineup.
A Capital-Light Deal With No Upfront Payments
The deal is built to be cheap upfront. Evolus pays no milestone fees at signing. It will buy Profhilo directly from IBSA under a transfer-price model, meaning it pays per unit rather than committing large sums early, per MarketScreener. Minimum purchase requirements only kick in during the fourth year after launch.
Evolus will fund all U.S. clinical trials and FDA approval work itself. That means the company carries the regulatory cost but keeps full control of the commercialization process. The structure is designed to align with Evolus' existing profit margins.
Exclusive U.S. Rights and a Path to More Products
The agreement goes beyond just one product. Under the deal's terms, Evolus gets the right to negotiate for additional products within the broader Profhilo brand family in the U.S. market, according to MarketScreener. That clause could expand the partnership well beyond this initial agreement.
IBSA is a Swiss multinational with a global footprint already established across 70-plus countries. Evolus plans to use that proven supply chain and brand recognition to accelerate U.S. growth. The Dermatology Digest noted the partnership expands access to Profhilo for both practitioners and patients nationwide.
Evolus Bets on an Underpenetrated U.S. Market
The skin-quality category is growing fast globally but remains largely untapped in the United States. No equivalent product currently holds FDA approval for this specific use. Evolus sees a first-mover opportunity. The company says the deal supports its near-term financial guidance, per TipRanks.
With Profhilo already trusted by millions of patients worldwide, Evolus is betting that U.S. demand will follow. The company now controls three distinct aesthetic categories: neurotoxins, dermal fillers, and skin quality. That broader portfolio could strengthen its position against larger rivals in a competitive market.
Sentiment
Mostly PositivePublishers
10
Articles
16
Reach
26
